Home / Business and Economy / GSK Bets Big on Allergy Cure
GSK Bets Big on Allergy Cure
20 Jan
Summary
- GSK acquired RAPT Therapeutics for $2.2 billion.
- A new drug, ozureprubart, targets severe food allergies.
- Potential blockbuster drug could launch by 2031.
GSK has announced a significant $2.2 billion acquisition of RAPT Therapeutics, a US-based biotech firm. This strategic move bolsters GSK's pipeline with ozureprubart (Ozu), a promising drug designed to combat severe food allergies.
Ozureprubart is an innovative, long-acting therapy currently in mid-stage clinical trials. It targets IgE, a crucial component in triggering allergic reactions to common foods like nuts, milk, and eggs.
Data from ongoing trials are anticipated next year, with large-scale studies planned for the second half of 2027. If successful, ozureprubart could be available by 2031, potentially generating over $1 billion annually for GSK.
This new treatment offers a significant advantage over existing therapies, which often involve burdensome injections every two to four weeks. Ozureprubart is administered quarterly, providing a much-needed option for many patients, including those ineligible for current treatments.
The acquisition grants GSK global rights to ozureprubart, excluding mainland China and its associated regions. This deal marks a major step for GSK's new leadership in addressing a critical unmet medical need.
